Diabetes and Metabolic Syndrome

Chapter

Abstract

Catheter-based renal denervation (RDN) reduces sympathetic nerve activity and blood pressure in patients with resistant hypertension [1, 2, 3]. Increased central sympathetic activity is a main contributor to the pathophysiology of several important chronic cardiovascular diseases, including diabetes and the metabolic syndrome. A body of preclinical and clinical evidence indicates the profound relationship between sympathetic overactivity and metabolic disorders. Indeed several recently published pilot studies and case reports suggest beneficial effects of RDN on glucose metabolism in patients with resistant hypertension.

Keywords

Metabolic syndrome Sympathetic activation Hyperinsulinemia Insulin resistance Resistant hypertension 

References

  1. 1.
    Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Mackintosh AF, Mary DA. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation. 2003;108(25):3097–101.PubMedCrossRefGoogle Scholar
  2. 2.
    Vollenweider P, Tappy L, Randin D, Schneiter P, Jequier E, Nicod P, Scherrer U. Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans. J Clin Invest. 1993;92(1):147–54.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Mancia G, Bousquet P, Elghozi JL, Esler M, Grassi G, Julius S, Reid J, Van Zwieten PA. The sympathetic nervous system and the metabolic syndrome. J Hypertens. 2007;25(5):909–20.PubMedCrossRefGoogle Scholar
  4. 4.
    Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996;275(20):1571–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Lima NK, Abbasi F, Lamendola C, Reaven GM. Prevalence of insulin resistance and related risk factors for cardiovascular disease in patients with essential hypertension. Am J Hypertens. 2009;22(1):106–11.PubMedCrossRefGoogle Scholar
  6. 6.
    Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet. 1980;1(8183):1373–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med. 2004;164(19):2147–55.PubMedCrossRefGoogle Scholar
  8. 8.
    The Emerging Risk Factors C. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–22.CrossRefGoogle Scholar
  9. 9.
    Gerstein HC. More insights on the dysglycaemia-cardiovascular connection. Lancet. 2010;375(9733):2195–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Brand-Miller J, Dickinson S, Barclay A, Celermajer D. The glycemic index and cardiovascular disease risk. Curr Atheroscler Rep. 2007;9(6):479–85.PubMedCrossRefGoogle Scholar
  11. 11.
    Hall JL, Matter CM, Wang X, Gibbons GH. Hyperglycemia inhibits vascular smooth muscle cell apoptosis through a protein kinase C-dependent pathway. Circ Res. 2000;87(7):574–80.PubMedCrossRefGoogle Scholar
  12. 12.
    de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, Oliveras A, Ruilope LM. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898–902.PubMedCrossRefGoogle Scholar
  13. 13.
    Grassi G, Dell’Oro R, Facchini A, Quarti Trevano F, Bolla GB, Mancia G. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens. 2004;22(12):2363–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Grassi G, Seravalle G, Quarti-Trevano F, Scopelliti F, Dell’Oro R, Bolla G, Mancia G. Excessive sympathetic activation in heart failure with obesity and metabolic syndrome: characteristics and mechanisms. Hypertension. 2007;49(3):535–41.PubMedCrossRefGoogle Scholar
  15. 15.
    Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO. Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension. 1993;21(5):618–23.PubMedCrossRefGoogle Scholar
  16. 16.
    Julius S, Gudbrandsson T, Jamerson K, Tariq Shahab S, Andersson O. The hemodynamic link between insulin resistance and hypertension. J Hypertens. 1991;9(11):983–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Schlaich MP, Hering D, Sobotka P, Krum H, Lambert GW, Lambert E, Esler MD. Effects of renal denervation on sympathetic activation, blood pressure, and glucose metabolism in patients with resistant hypertension. Front Physiol. 2012;3:10.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Scherrer U, Sartori C. Insulin as a vascular and sympathoexcitatory hormone: implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation. 1997;96(11):4104–13.PubMedCrossRefGoogle Scholar
  19. 19.
    Bardgett ME, McCarthy JJ, Stocker SD. Glutamatergic receptor activation in the rostral ventrolateral medulla mediates the sympathoexcitatory response to hyperinsulinemia. Hypertension. 2010;55(2):284–90.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85(7):2402–10.PubMedCrossRefGoogle Scholar
  21. 21.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Chen H, Sullivan G, Yue LQ, Katz A, Quon MJ. QUICKI is a useful index of insulin sensitivity in subjects with hypertension. Am J Physiol Endocrinol Metab. 2003;284(4):E804–12.PubMedGoogle Scholar
  23. 23.
    Yakubu-Madus FE, Johnson WT, Zimmerman KM, Dananberg J, Steinberg MI. Metabolic and hemodynamic effects of moxonidine in the Zucker diabetic fatty rat model of type 2 diabetes. Diabetes. 1999;48(5):1093–100.PubMedCrossRefGoogle Scholar
  24. 24.
    Rocchini AP, Mao HZ, Babu K, Marker P, Rocchini AJ. Clonidine prevents insulin resistance and hypertension in obese dogs. Hypertension. 1999;33(1 Pt 2):548–53.PubMedCrossRefGoogle Scholar
  25. 25.
    Prichard BN, Jager BA, Luszick JH, Kuster LJ, Verboom CN, Hughes PR, Sauermann W, Kuppers HE. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild to moderate essential hypertension. Blood Press. 2002;11(3):166–72.PubMedCrossRefGoogle Scholar
  26. 26.
    Lenski M, Mahfoud F, Razouk A, Ukena C, Lenski D, Barth C, Linz D, Laufs U, Kindermann I, Böhm M. Orthostatic function after renal sympathetic denervation in patients with resistant hypertension. Int J Cardiol 2013;169:418–24.PubMedCrossRefGoogle Scholar
  27. 27.
    Hering D, Lambert EA, Marusic P, Walton AS, Krum H, Lambert GW, Esler MD, Schlaich MP. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2013;61(2):457–64.PubMedCrossRefGoogle Scholar
  28. 28.
    Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Böhm M. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123(18):1940–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Schlaich MP, Straznicky N, Grima M, Ika-Sari C, Dawood T, Mahfoud F, Lambert E, Chopra R, Socratous F, Hennebry S, Eikelis N, Böhm M, Krum H, Lambert G, Esler MD, Sobotka PA. Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens. 2011;29(5):991–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Luippold G, Beilharz M, Muhlbauer B. Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats. NDT. 2004;19(2):342–7.PubMedGoogle Scholar
  31. 31.
    Strojek K, Grzeszczak W, Gorska J, Leschinger MI, Ritz E. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol. 2001;12(3):602–5.PubMedGoogle Scholar
  32. 32.
    Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C, Linz D, Schmieder R, Rump LC, Kindermann I, Sobotka PA, Krum H, Scheller B, Schlaich M, Laufs U, Böhm M. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension. 2012;60(2):419–24.PubMedCrossRefGoogle Scholar
  33. 33.
    Narkiewicz K, van de Borne PJ, Cooley RL, Dyken ME, Somers VK. Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation. 1998;98(8):772–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Witkowski A, Prejbisz A, Florczak E, Kadziela J, Sliwinski P, Bielen P, Michalowska I, Kabat M, Warchol E, Januszewicz M, Narkiewicz K, Somers VK, Sobotka PA, Januszewicz A. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58(4):559–65.PubMedCrossRefGoogle Scholar
  35. 35.
    Krum H, Barman N, Schlaich M, Sobotka P, Esler M, Mahfoud F, Böhm M, Dunlap M. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911–7.CrossRefGoogle Scholar
  36. 36.
    Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361(9):932–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2015

Authors and Affiliations

  1. 1.Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische IntensivmedizinUniversitätsklinikum des SaarlandesHomburg/SaarGermany

Personalised recommendations